Get the Stockscreener App
1.861
5.97%
-0.149
Salarius Pharmaceuticals Inc stock is traded at $1.861, with a volume of 32,487.
It is down -5.97% in the last 24 hours and up +10.53% over the past month.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
See More
Previous Close:
$2.01
Open:
$2.01
24h Volume:
32,487
Relative Volume:
0.02
Market Cap:
$3.18M
Revenue:
$4.70M
Net Income/Loss:
$-4.99M
P/E Ratio:
-0.2899
EPS:
-6.42
Net Cash Flow:
$-5.29M
1W Performance:
-15.63%
1M Performance:
+10.53%
6M Performance:
-19.92%
1Y Performance:
-58.02%
1-Day Range:
$1.86
$2.0399
1-Week Range:
$1.86
$2.38
52-Week Range:
$1.22
$7.20
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Name
Salarius Pharmaceuticals Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Compare SLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
1.8903 | 3.18M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.89 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.62 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.19 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.97 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.44 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Stock (SLRX) Latest News
What Recent Market Trends Mean for Salarius Pharmaceuticals Inc’s (SLRX) Stock - The News Heater
Salarius resumes trial for MDS and CMML treatment - Investing.com India
Salarius resumes trial for MDS and CMML treatment By Investing.com - Investing.com Australia
Salarius Pharmaceuticals Announces Patient Enrollment to - GlobeNewswire
Breakthrough Cancer Treatment Shows Triple Survival Time: Trial Back on Track - StockTitan
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt - Benzinga
Deal Watch: Bausch Companies Set Hectic Pace At J.P. Morgan With Five Deals - News & Insights
Salarius Pharmaceuticals and Decoy Therapeutics announce merger - MSN
Stock market news: Phio Pharmaceuticals -50.61%, Salarius Pharmaceuticals -28.61% among biggest losers during mid day trading - Business Upturn
Stock market today: Phio Pharmaceuticals -41.48%, Aehr Test Systems -26.86% among biggest losers in early trading - Business Upturn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
Premier of separatist Moldova region says gas cutoff shattered foreign trade - Yahoo! Voices
Biologics Contract Development And Manufacturing Organization (CDMO) Market size to increase by USD 16.32 Billion between 2024 to 2029, Market Segmentation by Type, Product Type, Geography , Technavio - Yahoo Finance
Here’s Why Chimerix, Inc. (CMRX) Is Skyrocketing - Yahoo Finance
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Here’s Why Cidara Therapeutics, Inc. (CDTX) Is Skyrocketing - Yahoo Finance
Here’s Why Solaris Energy Infrastructure, Inc. (SEI) Is Skyrocketing - Yahoo Finance
Houston's Salarius Pharmaceuticals to merge with Gates Foundation-backed co., focus on Covid-19 treatment - The Business Journals
Biogen Offers to Buy Remaining Stake in Sage Therapeutics - Yahoo Finance
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge - Benzinga
Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On MondayHere's Why - Yahoo Finance
Thermo Fisher Scientific Inc. (TMO): A Bull Case Theory - Yahoo Finance
Stock market news: Phio Pharmaceuticals +296.88%, Salarius Pharmaceuticals +153.67% among top gainers during mid day trading - Business Upturn
FDA approves Zeiss Medical Technology’s MEL 90 excimer laser - Yahoo! Voices
MercadoLibre, Inc. (MELI): A Bull Case Theory - Yahoo Finance
Stock market news: Shallgo saw rise of 286.81% while Kairos Pharma was up by 176.47% during mid day trading - Business Upturn
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge - Benzinga
Illumina and NVIDIA Just Dropped a Genomics Bombshell - Yahoo Finance
Xiaohongshu, China's answer to Instagram, hits no. 1 on the App Store as TikTok faces US shutdown - Yahoo! Voices
Why Madrigal Pharmaceuticals Stock Is Sinking Today - Yahoo! Voices
Gilead and LEO Pharma link on programmes for inflammatory conditions - Yahoo! Voices
US Stocks Mixed; Nasdaq Down Over 1% - Benzinga
Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 billion - Yahoo Finance
Stock market today: Phio Pharmaceuticals +289.93%, Sage Therapeutics +34.95% among the top gainers in early trading - Business Upturn
InboxArmy CEO Scott Cohen Appointed as New Committee Co-Chair for ANA Email Excellence Center - Yahoo Finance
Stock market today: Kairos Pharma saw rise of 130.20% and Salarius Pharmaceuticals was up by 180.52% in early trading - Business Upturn
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
Salarius Pharmaceuticals Merges with Decoy Therapeutics - TipRanks
Salarius Pharmaceuticals to Merge with Decoy Therapeutics - MarketWatch
Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement - The Manila Times
Ekso Bionics Reports Certain Preliminary Fourth Quarter 2024 Financial Results - The Manila Times
Salarius, Decoy Therapeutics enter definitive merger agreement - TipRanks
Salarius Pharma Merges with AI Drug Designer Decoy Therapeutics, Plans Pan-Coronavirus Drug - StockTitan
Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762 - Yahoo Finance
Illumina, Nvidia team to use AI in foundation models - Yahoo Finance
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug - Yahoo Finance
Bexion Pharmaceuticals, Inc. Announces Poster Presentation at ASCO GI 2025 - Yahoo Finance
Axcelis Technologies Inc (NASDAQ:ACLS): Vulnerable to Disruption and Market Downturns - Yahoo Finance
Salarius Pharmaceuticals Inc Stock (SLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):